Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02958787 · ClinicalTrials.gov registry record · Phase 2
Vessel Sparing Prostate Radiation Therapy
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
NCT02958787 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 135 participants.
The verdict
NCT02958787, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
Study Summary
Prostate cancer patients have a number of excellent treatment options to consider, and quality of life following treatment is often a consideration in treatment choice. One critical quality of life concern for patients diagnosed with prostate cancer is sexual function. Previous studies point to a vascular mechanism of impotence post-radiation therapy, as opposed to a nerve-based mechanism following surgery. In this study, the critical vascular structures (internal pudendal artery and corpus cavernosum) are defined by MRI-based imaging and included in treatment planning for radiation treatments, hopefully preserving critical artery function. This study will collect erectile function preservation rates at 5-years post-vessel-sparing radiotherapy with or without aids using the patient reported using the simplified three-question erectile function scale.
Interventions
- RADIATION Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2004-11 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02958787
The ClinicalTrials.gov registry entry for NCT02958787 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Radiation Therapy is the first listed.
NCT02958787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02958787 about?
NCT02958787 is a clinical study titled "Vessel Sparing Prostate Radiation Therapy". Prostate cancer patients have a number of excellent treatment options to consider, and quality of life following treatment is often a consideration in treatment choice. One critical quality of life concern for patients diagnosed with prostate cancer is sexual function. Previous studies point to a va...
What is the current status of trial NCT02958787?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2004-11. Estimated completion is 2009-10.
What interventions are being tested in trial NCT02958787?
The interventions under investigation include: Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT02958787?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.